Phase 2 Study to Investigate the Efficacy, Safety, and Tolerability of Six Weeks Treatment With V565 in Subjects With Active Crohn's Disease

Trial Profile

Phase 2 Study to Investigate the Efficacy, Safety, and Tolerability of Six Weeks Treatment With V565 in Subjects With Active Crohn's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs V 565 (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms HarbOR
  • Most Recent Events

    • 07 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 1 May 2018.
    • 13 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 08 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top